Skip to main content
. 2016 Jun 15;36(13):1836–1855. doi: 10.1128/MCB.00189-16

TABLE 1.

Tumor take rates of 786-O cells depending upon on VHL status and sunitinib treatment

VHL status Treatment Tumor take rate (%) (no. of samples with tumors/total no. of samples)
Deficient Vehicle (n = 21) 81.0 (17/21)
Reconstituted Vehicle (n = 9) 11.1 (1/9)
Deficient Sunitinib (n = 21) 57.1 (12/21)